Results 151 to 160 of about 1,420 (176)
Some of the next articles are maybe not open access.
Pilot Study of Droxidopa With Carbidopa in Adults With ADHD
Journal of Attention Disorders, 2015Objective: We conducted a two-period (open-label and double-blind) pilot investigation of droxidopa, with and without carbidopa, for ADHD. Method: Twenty adult ADHD patients received open-label droxidopa titrated from 200 to 600 mg 3 times per day (TID; Weeks 1-3), then open-label droxidopa plus carbidopa titrated from 25 or 50 mg TID (Weeks 4-6).
Lenard A, Adler, Stephen W, Gorny
openaire +2 more sources
Droxidopa approved for neurogenic orthostatic hypotension
American Journal of Health-System Pharmacy, 2014Droxidopa, a synthetic amino acid precursor of norepinephrine, has been approved as oral therapy for the treatment of neurogenic orthostatic hypotension, FDA and Chelsea Therapeutics announced on February 18.
openaire +1 more source
Treatment of hemodialysis-induced hypotension with oral droxidopa.
Journal of Japanese Society for Dialysis Therapy, 1991血液透析 (HD) 中の低血圧発作 (HIH) は深刻な合併症である. ドロキシドパ (DOPS) は, 経口投与が可能なnorepinephrine (NE) 前駆アミノ酸で, Shy-Drager症候群などに見られる起立性低血圧に臨床応用されている. 我々はすでに, HD患者においてもDOPSが有効に吸収されNEに変換し, HIHに対して有効例の存在することを報告した. そこで今回, 多施設における初期第II相試験を行い, 用量設定に関しても検討した. 5施設において, 処置を要するHIHを呈した週3回の慢性HD患者34例 (男14例, 糖尿病性腎不全〔DM〕12例) を対象とした.
Yoshiharu Tsubakihara +7 more
openaire +1 more source
[Study on the metabolism of droxidopa in humans].
Rinsho shinkeigaku = Clinical neurology, 1995Supplement of the deficient neurotransmitters is one of the most effective therapies for neurodegenerative disorders. For the treatment of Parkinson's disease, L-DOPA therapy has been applied to replace dopamine, and droxidopa (L-threo-3,4-dihydroxyphenylserine) therapy to supply noradrenaline (NA).
W, Maruyama, M, Naoi, H, Narabayashi
openaire +1 more source
Successful Treatment of Refractory Orthostatic Intolerance (OI) With Droxidopa
Clinical Pediatrics, 2022Christina Kokorelis +3 more
openaire +2 more sources